Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer

Kevin Kris Warnakula Olesen; Matt Wheeler; John W. Eikelboom

doi:10.1055/s-0039-3402809

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2020; 120(02): 194-196
DOI: 10.1055/s-0039-3402809

Invited Editorial Focus

Georg Thieme Verlag KG Stuttgart · New York

Oral Anticoagulant Treatment in Patients with Atrial Fibrillation and Cancer

Kevin Kris Warnakula Olesen

¹Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark

,

Matt Wheeler

²Population Health Research Institute, Hamilton Health Sciences and McMaster University, Ontario, Canada

,

John W. Eikelboom

²Population Health Research Institute, Hamilton Health Sciences and McMaster University, Ontario, Canada

› Author Affiliations

Abstract

Full Text

References

References
1 Lip GYH, Banerjee A, Boriani G. , et al. Antithrombotic therapy for atrial fibrillation: chest guideline and expert panel report. Chest 2018; 154 (05) 1121-1201
2 Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in atrial fibrillation: Past, present and future. Comparing the guidelines and practical decision-making. ThrombHaemost 2017; 117 (07) 1230-1239
3 Ruff CT, Giugliano RP, Braunwald E. , et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet 2014; 383 (9921): 955-962
4 Li XS, Deitelzweig S, Keshishian A. , et al. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice. A propensity-matched analysis of 76,940 patients. ThrombHaemost 2017; 117 (06) 1072-1082
5 Hohnloser SH, Basic E, Hohmann C, Nabauer M. Effectiveness and safety of non-vitamin k oral anticoagulants in comparison to phenprocoumon: data from 61,000 patients with atrial fibrillation. ThrombHaemost 2018; 118 (03) 526-538
6 Potpara TS, Poposka L. The challenge of thromboprophylaxis in cancer patients-balancing the thrombotic and bleeding risks. ThrombHaemost 2018; 118 (08) 1347-1349
7 Prandoni P, Lensing AW, Piccioli A. , et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100 (10) 3484-3488
8 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
9 Young AM, Marshall A, Thirlwall J. , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J ClinOncol 2018; 36 (20) 2017-2023
10 McBane II R, Wysokinski WE, Le-Rademacher JG. , et al. Apixaban and dalteparin in active malignancy associated venous thromboembolism: the ADAM VTE trial. J ThrombHaemost 2019 . Doi: 10.1111/jth.14662
11 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: burden, mechanisms, and management. ThrombHaemost 2017; 117 (02) 219-230
12 Chu G, Versteeg HH, Verschoor AJ. , et al. Atrial fibrillation and cancer - An unexplored field in cardiovascular oncology. Blood Rev 2019; 35: 59-67
13 Steffel J, Verhamme P, Potpara TS. , et al; ESC Scientific Document Group. The 2018 European heart rhythm association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 2018; 39 (16) 1330-1393
14 Cavallari I, Verolino G, Romano S. , et al. Efficacy and safety of non-vitamin K oral anticoagulants in patients with atrial fibrillation and cancer: a study-level meta-analysis. Thromb Haemost 2020; 120 (02) 314-321
15 Fanola CL, Ruff CT, Murphy SA. , et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation: analysis of the ENGAGE AF - TIMI 48 trial. J Am Heart Assoc 2018; 7 (16) e008987
16 Melloni C, Dunning A, Granger CB. , et al. Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and a history of cancer: insights from the ARISTOTLE trial. Am J Med 2017; 130 (12) 1440-1448
17 Chen ST, Hellkamp AS, Becker RC. , et al. Efficacy and safety of rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation and a history of cancer: observations from ROCKET AF. Eur Heart J Qual Care Clin Outcomes 2019; 5 (02) 145-152
18 Ording AG, Horváth-Puhó E, Adelborg K, Pedersen L, Prandoni P, Sørensen HT. Thromboembolic and bleeding complications during oral anticoagulation therapy in cancer patients with atrial fibrillation: a Danish nationwide population-based cohort study. Cancer Med 2017; 6 (06) 1165-1172
19 Kim K, Lee YJ, Kim TH. , et al. Effect of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients with newly diagnosed cancer. Korean Circ J 2018; 48 (05) 406-417
20 Shah S, Norby FL, Datta YH. , et al. Comparative effectiveness of direct oral anticoagulants and warfarin in patients with cancer and atrial fibrillation. Blood Adv 2018; 2 (03) 200-209
21 Deng Y, Tong Y, Deng Y, Zou L, Li S, Chen H. Non-vitamin K antagonist oral anticoagulants versus warfarin in patients with cancer and atrial fibrillation: a systematic review and meta-analysis. J Am Heart Assoc 2019; 8 (14) e012540
22 Büller HR, Décousus H, Grosso MA. , et al; Hokusai-VTE Investigators. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369 (15) 1406-1415
23 Schulman S, Kearon C, Kakkar AK. , et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361 (24) 2342-2352
24 Agnelli G, Buller HR, Cohen A. , et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369 (09) 799-808
25 Bauersachs R, Berkowitz SD, Brenner B. , et al; EINSTEIN Investigators. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363 (26) 2499-2510
26 Gelosa P, Castiglioni L, Tenconi M. , et al. Pharmacokinetic drug interactions of the non-vitamin K antagonist oral anticoagulants (NOACs). Pharmacol Res 2018; 135: 60-79
27 Delluc A, Wang TF, Yap ES. , et al. Anticoagulation of cancer patients with non-valvular atrial fibrillation receiving chemotherapy: Guidance from the SSC of the ISTH. J ThrombHaemost 2019; 17 (08) 1247-1252